Fintel reports that on September 26, 2023, Oppenheimer upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Perform to Outperform.
Analyst Price Forecast Suggests 42.38% Upside
As of August 31, 2023, the average one-year price target for Edwards Lifesciences is 98.90. The forecasts range from a low of 75.75 to a high of $115.50. The average price target represents an increase of 42.38% from its latest reported closing price of 69.46.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Edwards Lifesciences is 5,940MM, an increase of 5.00%. The projected annual non-GAAP EPS is 2.59.
What is the Fund Sentiment?
There are 2333 funds or institutions reporting positions in Edwards Lifesciences. This is an increase of 288 owner(s) or 14.08% in the last quarter. Average portfolio weight of all funds dedicated to EW is 0.41%, an increase of 29.69%. Total shares owned by institutions increased in the last three months by 87.11% to 1,051,845K shares. The put/call ratio of EW is 0.52, indicating a bullish outlook.
What are Other Shareholders Doing?
BBCPX – Bridge Builder Core Plus Bond Fund holds 379,121K shares representing 62.36% ownership of the company. In it’s prior filing, the firm reported owning 363,868K shares, representing an increase of 4.02%. The firm increased its portfolio allocation in EW by 6.19% over the last quarter.
Six Circles Trust – Six Circles Global Bond Fund holds 66,854K shares representing 11.00% ownership of the company. In it’s prior filing, the firm reported owning 11,518K shares, representing an increase of 82.77%. The firm increased its portfolio allocation in EW by 491.63% over the last quarter.
Capital International Investors holds 27,015K shares representing 4.44% ownership of the company. In it’s prior filing, the firm reported owning 25,759K shares, representing an increase of 4.65%. The firm increased its portfolio allocation in EW by 12.15% over the last quarter.
BBTBX – Bridge Builder Core Bond Fund holds 21,185K shares representing 3.48% ownership of the company. In it’s prior filing, the firm reported owning 11,755K shares, representing an increase of 44.51%. The firm increased its portfolio allocation in EW by 83.68% over the last quarter.
DCFFX – Destinations Core Fixed Income Fund Class I holds 20,675K shares representing 3.40% ownership of the company.
Edwards Lifesciences Background Information
(This description is provided by the company.)
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
This article originally appeared on Fintel
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
